Welcome to the e-CCO Library!

P574: Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn‘s disease
Year: 2022
Source: ECCO'22
Authors: Suleiman, A.(1);Goebel, A.(1);Bhatnagar, S.(2);D'Cunha, R.(2);Liu, W.(2);Pang, Y.(2);
Created: Friday, 11 February 2022, 3:56 PM
P574: The effects of vagus nerve stimulation in biologic-refractory Crohn’s disease: A prospective clinical trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. D'Haens1*, Z. Cabrijan2, M. Eberhardson3, R. van den Bergh1, M. Löwenberg1, G. Fiorino4, S. Danese4, Y. Levine5, D. Chernoff5

Created: Thursday, 21 February 2019, 9:14 AM
P575 Real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn’s disease: The Scottish ustekinumab cohort
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. PLEVRIS1, A. Robertson2, J. Fulforth1, R. Hall3, I. Campbell4, C. Kane5, J. Veryan6, W. Lam6, J. Saunders2, P. Jenkinson1, C. Chuah7, C. Kelly8, D. Watts8, D. Gaya6, J. Macdonald9, H. Jafferbhoy7, J.P. Seenan9, C. Mowat3, D. Sutherland2, G. Naismith10, G. Bain5, I. Arnott1, G. Jones1, C. Lees1

Created: Thursday, 30 January 2020, 10:12 AM
P575: AZA-related toxicity isn't aggravated by concomitant drugs in IBD patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ladic A., Bozina N., Cukovic-Cavka S., Krznaric Z.

Created: Wednesday, 20 February 2019, 10:36 AM
P575: Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Siegmund, B.(1)*;Komori, H.K.(2);Abreu, M.T.(3);Vermeire, S.(4);Dotan, I.(5,6);Goetsch, M.(7);Crosby, C.(8);Ryan, R.(9);Woolcott, J.(10);Danese, S.(11);
Created: Friday, 14 July 2023, 11:05 AM
P575: Nutrition and Inflammatory Bowel Disease – a nationwide survey of patients, gastroenterologists and dietitians
Year: 2021
Source: ECCO'21 Virtual
Authors: McCarthy, N.(1);Schultz, M.(2);Wall, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P575: Safety and efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn’s disease after cyclophosphamide-free mobilisation: Preliminary Results
Year: 2022
Source: ECCO'22
Authors: Giordano, A.(1);Rovira, M.(2);Barastegui, R.(1);Marín, P.(2);Martínez, N.(2);Fernández-Aviles, F.(2);Suárez-Lledó, M.(2);Doménech, A.(2);Ordás, I.(1);Fernández-Clotet, A.(1);Caballol, B.(1);Gallego, M.(1);Vara, A.(1);Masamunt, M.C.(1);Giner, A.(1);Corraliza, A.M.(3);Panés, J.(1);Salas, A.(3);Ricart, E.(1);
Created: Friday, 11 February 2022, 3:56 PM
P575: Simple novel tacrolimus enemas are very effective in severe refractory proctitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

S. R. Fehily*1, F. C. Martin1, M. A. Kamm1,2

Created: Friday, 22 February 2019, 9:41 AM
P575: Vedolizumab trough levels predict clinical outcomes in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Guidi1*, D. Pugliese1, T. Panici Tonucci1, B. Tolusso2, C. Felice1, C. Di Mario2, A. Papa1, E. Gremese2, A. Gasbarrini3, G.L. Rapaccini1, A. Armuzzi1

Created: Thursday, 21 February 2019, 9:14 AM
P576 The value of small bowel capsule endoscopy in the change of therapeutic management in patients with established Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Viazis1, E. Tsoukali1, C. Pontas1, G. Karampekos1, F. Gkeros1, G. Filippidis1, M. Vraka1, K. Koustenis1, K. Mountaki1, I. Mitselos2, M. Mela1, A. Christidou1, E. Archavlis1, E. Vienna1, D. Christodoulou2, G. Mantzaris1

Created: Thursday, 30 January 2020, 10:12 AM
P576: Could the hyperbaric oxygen therapy be an effective adjuvant therapy for fistulising Crohn's disease?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Piotrowicz G.*1, Kowerzanow J.2, Banaszkiewicz P.2, Babicki A.2, Kot J.3, Rydzewska G.4

Created: Wednesday, 20 February 2019, 10:36 AM
P576: Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CD
Year: 2023
Source: ECCO’23 Copenhagen
Authors: D'Haens, G.(1)*;Bossuyt, P.(2);Baert, F.(3);Molnár, T.(4);Clasquin, E.(1);Lowenberg, M.(1);Montazeri, N.(1);Peeters, H.(5);Lambrecht, G.(6);Vermeire, S.(7);
Created: Friday, 14 July 2023, 11:05 AM
P576: Impact of improved access to biologic therapies and physician engagement on excess steroid exposure: Results from a UK audit of 3561 patients
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Selinger1, G.C. Parkes2*, M. Adamson3, A. Bassi4, F. Donovan5, A. Fraser6, B. George7, L. Grey8, V. Hall9, J. Lindi10, H. Ludlow11, I. Parisi12, P. Patel13, R. Pollock14, S. Salunke15, J. Saunders16, G. Scott17, M. Smith18, T. Raine19

Created: Thursday, 21 February 2019, 9:14 AM
P576: Real-world effectiveness and safety of risankizumab in patients with moderate-to-severe multi-refractory Crohn’s disease: a Belgian multi-centric cohort study
Year: 2022
Source: ECCO'22
Authors: Alsoud, D.(1);Franchimont, D.(2);D'Heygere, F.(3);Bossuyt, P.(4);Vijverman, A.(5);Van Hootegem, P.(6);Sabino, J.(1,7);Cremer, A.(2);Vermeire, S.(1,7);Ferrante, M.(1,7);
Created: Friday, 11 February 2022, 3:56 PM
P576: Therapeutic drug monitoring as predictive marker of mucosal healing in Crohn’s disease patients treated with anti-TNF: a prospective multi-centre study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

L. Bertani*1, G. Bodini2, G. Mondello1, M. G. Mumolo3, S. Maltinti1, I. Baldissarro2, G. Tapete1, E. Albano1, L. Ceccarelli3, M. Crespi2, V. Savarino2, S. Marchi1, F. Costa3

Created: Friday, 22 February 2019, 9:41 AM
P576: Ustekinumab levels correlate with induction fecal calprotectin drop-slope and discriminate the need for intensification at week 52 in Crohn's Disease patients.
Year: 2021
Source: ECCO'21 Virtual
Authors: Mateos, B.(1);Sáez-González, E.(2);Iborra, M.(2);Moret, I.(1);Cañada, A.(3);Tortosa, L.(1);Bastida, G.(2);Aguas, M.(2);Cerrillo, E.(2);Nos, P.(2);Beltrán, B.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P577 Ustekinumab in actual clinical practice: our centre experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

J.M. LOPEZ TOBARUELA, A.D. Sanchez-Capilla, E.J. Ortega-Suazo, M.C. Fernandez-Cano, M. Herrador-Paredes, M.J. Cabello-Tapia, M.M. Martin-Rodriguez

Created: Thursday, 30 January 2020, 10:12 AM
P577: “Treat to target” recommendations in ulcerative colitis in practice: clinician perceptions and potential barriers
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Bryant R.*1,2, Costello S.1,3, Schoeman S.4, Sathananthan D.4, Lau S.3, Schoeman M.4, Mountifield R.1,5, Tee D.6, Travis S.7,8, Andrews J.1,9

Created: Wednesday, 20 February 2019, 10:36 AM
P577: A Phase 1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the Nucleotide-binding oligomerization domain, Leucine rich Repeat containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1)*;Danese, S.(2);Colombel, J.F.(3);Rieder, F.(4);Yarur, A.(5);Verstockt, B.(6);Lichtiger, S.(7);Mosig, R.(8);Cataldi, F.(7);Feagan, B.(9);
Created: Friday, 14 July 2023, 11:05 AM
P577: A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Orlando1*, F.S. Macaluso1, W. Fries2, A.C. Privitera3, M. Cappello4, S. Siringo5, G. Inserra6, A. Magnano7, R. Di Mitri8, N. Belluardo9, G. Scarpulla10, G. Magrì11, N. Trovatello12, A. Carroccio13, S. Genova14, C. Bertolami15, R. Vassallo16, M. Ventimiglia1, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Created: Thursday, 21 February 2019, 9:14 AM